{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:50:54Z","timestamp":1790844654418,"version":"4.1.0"},"reference-count":171,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["135477"],"award-info":[{"award-number":["135477"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\"><jats:title>Background<\/jats:title>\n<jats:p>Magnetic resonance imaging localises cancer in the prostate, allowing for a targeted biopsy with or without transrectal ultrasound-guided systematic biopsy. Targeted biopsy methods include cognitive fusion, where prostate lesions suspicious on magnetic resonance imaging are targeted visually during live ultrasound, and software fusion, where computer software overlays the magnetic resonance imaging image onto the ultrasound in real time. The effectiveness and cost-effectiveness of software fusion technologies compared with cognitive fusion biopsy are uncertain.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-2\"><jats:title>Objectives<\/jats:title>\n<jats:p>To assess the clinical and cost-effectiveness of software fusion biopsy technologies in people with suspected localised and locally advanced prostate cancer.<\/jats:p>\n<jats:p>A systematic review was conducted to evaluate the diagnostic accuracy, clinical efficacy and practical implementation of nine software fusion devices compared to cognitive fusion biopsies, and with each other, in people with suspected prostate cancer. Comprehensive searches including MEDLINE, and Embase were conducted up to August 2022 to identify studies which compared software fusion and cognitive fusion biopsies in people with suspected prostate cancer. Risk of bias was assessed with quality assessment of diagnostic accuracy studies-comparative tool.<\/jats:p>\n<jats:p>A network meta-analysis comparing software and cognitive fusion with or without concomitant systematic biopsy, and systematic biopsy alone was conducted. Additional outcomes, including safety and usability, were synthesised narratively.<\/jats:p>\n<jats:p>A de novo decision model was developed to estimate the cost-effectiveness of targeted software fusion biopsy relative to cognitive fusion biopsy with or without concomitant systematic biopsy for prostate cancer identification in biopsy-naive people. Scenario analyses were undertaken to explore the robustness of the results to variation in the model data sources and alternative assumptions.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-3\"><jats:title>Results<\/jats:title>\n<jats:p>Twenty-three studies (3773 patients with software fusion, 2154 cognitive fusion) were included, of which 13 informed the main meta-analyses. Evidence was available for seven of the nine fusion devices specified in the protocol and at high risk of bias.<\/jats:p>\n<jats:p>The meta-analyses show that patients undergoing software fusion biopsy may have: (1) a lower probability of being classified as not having cancer, (2) similar probability of being classified as having non-clinically significant cancer (International Society of Urological Pathology grade 1) and (3) higher probability of being classified at higher International Society of Urological Pathology grades, particularly International Society of Urological Pathology 2. Similar results were obtained when comparing between same biopsy methods where both were combined with systematic biopsy. Evidence was insufficient to conclude whether any individual devices were superior to cognitive fusion, or whether some software fusion technologies were superior to others.<\/jats:p>\n<jats:p>Uncertainty in the relative diagnostic accuracy of software fusion versus cognitive fusion reduce the strength of any statements on its cost-effectiveness. The economic analysis suggests incremental cost-effectiveness ratios for software fusion biopsy versus cognitive fusion are within the bounds of cost-effectiveness (\u00a31826 and \u00a35623 per additional quality-adjusted life-year with or with concomitant systematic biopsy, respectively), but this finding needs cautious interpretation.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-4\"><jats:title>Limitations<\/jats:title>\n<jats:p>There was insufficient evidence to explore the impact of effect modifiers.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-5\"><jats:title>Conclusions<\/jats:title>\n<jats:p>Software fusion biopsies may be associated with increased cancer detection in relation to cognitive fusion biopsies, but the evidence is at high risk of bias. Sufficiently powered, high-quality studies are required. Cost-effectiveness results should be interpreted with caution given the limitations of the diagnostic accuracy evidence.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-6\"><jats:title>Study registration<\/jats:title>\n<jats:p>This trial is registered as PROSPERO CRD42022329259.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-7\"><jats:title>Funding<\/jats:title>\n<jats:p>This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: 135477) and is published in full in <jats:italic>Health Technology Assessment<\/jats:italic>; Vol. 28, No. 61. See the NIHR Funding and Awards website for further information.<\/jats:p>\n<\/jats:sec>","DOI":"10.3310\/plfg4210","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T10:39:29Z","timestamp":1728124769000},"page":"1-310","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["MRI software and cognitive fusion biopsies in people with suspected prostate cancer: a systematic review, network meta-analysis and cost-effectiveness analysis"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4569-5136","authenticated-orcid":true,"given":"Alexis","family":"Llewellyn","sequence":"first","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6193-4673","authenticated-orcid":true,"given":"Thai Han","family":"Phung","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-8513","authenticated-orcid":true,"given":"Marta","family":"O Soares","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6803-5566","authenticated-orcid":true,"given":"Lucy","family":"Shepherd","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0989-1984","authenticated-orcid":true,"given":"David","family":"Glynn","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-6869","authenticated-orcid":true,"given":"Melissa","family":"Harden","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2765-7363","authenticated-orcid":true,"given":"Ruth","family":"Walker","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0528-4773","authenticated-orcid":true,"given":"Ana","family":"Duarte","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-0221","authenticated-orcid":true,"given":"Sofia","family":"Dias","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2024,10]]},"reference":[{"key":"key2024100516033300_ref1-bib1","volume-title":"Ten Most Common Cancers in Males","author":"Cancer Research UK","year":"2021"},{"key":"key2024100516033300_ref2-bib2","volume-title":"Cancer Registration Statistics, England: Final Release","author":"Public Health England","year":"2018"},{"key":"key2024100516033300_ref3-bib3","volume-title":"Prostate Cancer Statistics: Prostate Cancer Incidence","author":"Cancer Research UK","year":"2017"},{"key":"key2024100516033300_ref5-bib5","first-page":"455","article-title":"Update on prostate cancer in black men within the UK","volume":"8","author":"Jones","year":"2014","journal-title":"Ecancermedicalscience"},{"key":"key2024100516033300_ref6-bib6","doi-asserted-by":"crossref","first-page":"e27130","DOI":"10.1371\/journal.pone.0027130","article-title":"An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis","volume":"6","author":"Kici\u0144ski","year":"2011","journal-title":"PLOS ONE"},{"key":"key2024100516033300_ref7-bib7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4111\/icu.20210415","article-title":"Prevalence and risk factors for incidental prostate cancer in patients after transurethral resection of the prostate with negative results on prostate biopsy: a retrospective study","volume":"63","author":"Guo","year":"2022","journal-title":"Investig Clin Urol"},{"key":"key2024100516033300_ref8-bib8","doi-asserted-by":"crossref","first-page":"e3502","DOI":"10.1136\/bmj.e3502","article-title":"Preventing overdiagnosis: how to stop harming the healthy","volume":"344","author":"Moynihan","year":"2012","journal-title":"BMJ"},{"key":"key2024100516033300_ref9-bib9","doi-asserted-by":"crossref","first-page":"e026960","DOI":"10.1136\/bmjopen-2018-026960","article-title":"Resisting recommended treatment for prostate cancer: a qualitative analysis of the lived experience of possible overdiagnosis","volume":"9","author":"McCaffery","year":"2019","journal-title":"BMJ Open"},{"key":"key2024100516033300_ref13-bib13","volume-title":"Consensus Statements on PSA Testing in Asymptomatic Men in the UK: Information for Health Professionals \u2013 Prostate Cancer UK","author":"Prostate Cancer UK","year":"2016"},{"key":"key2024100516033300_ref15-bib15","volume-title":"Faster Diagnosis Standard","author":"NHS England"},{"key":"key2024100516033300_ref16-bib16","volume-title":"Quality Statement 1: Direct Access to Diagnostic Tests \u2013 Suspected Cancer: Quality Standard [QS124]","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"key2024100516033300_ref18-bib18","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1200\/JCO.2016.34.15_suppl.5000","article-title":"The PROMIS study: a paired-cohort, blinded confirmatory study evaluating the accuracy of multi-parametric MRI and TRUS biopsy in men with an elevated PSA","volume":"34","author":"Ahmed","year":"2016","journal-title":"J Clin Oncol"},{"key":"key2024100516033300_ref19-bib19","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"key2024100516033300_ref20-bib20","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","article-title":"ESUR prostate MR guidelines 2012","volume":"22","author":"Barentsz","year":"2012","journal-title":"Eur Radiol"},{"key":"key2024100516033300_ref21-bib21","volume-title":"Annual Review of Medicine","author":"Turkbey","year":"2019"},{"key":"key2024100516033300_ref22-bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS prostate imaging: reporting and data system: 2015, version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur Urol"},{"key":"key2024100516033300_ref25-bib25","doi-asserted-by":"crossref","first-page":"894.e1","DOI":"10.1016\/j.crad.2019.06.004","article-title":"Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways","volume":"74","author":"Barrett","year":"2019","journal-title":"Clin Radiol"},{"key":"key2024100516033300_ref26-bib26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bju.14759","article-title":"Biparametric vs. multiparametric prostate magnetic resonance imaging for the detection of prostate cancer in treatment-na\u00efve patients: a diagnostic test accuracy systematic review and meta-analysis","volume":"124","author":"Alabousi","year":"2019","journal-title":"BJU Int"},{"key":"key2024100516033300_ref27-bib27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/bju.15337","article-title":"Local anaesthetic transperineal (LATP) prostate biopsy using a probe-mounted transperineal access system: a multicentre prospective outcome analysis","volume":"128","author":"Lopez","year":"2021","journal-title":"BJU Int"},{"key":"key2024100516033300_ref28-bib28","volume-title":"NICE Recommends New Diagnostic Devices for Men with Suspected Prostate Cancer in Draft Guidance","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"key2024100516033300_ref29-bib29","volume-title":"Transperineal Biopsy for Diagnosing Prostate Cancer: In Development [GID-DG10043]","author":"National Institute for Health and Care Excellence"},{"key":"key2024100516033300_ref30-bib30","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1089\/end.2015.0450","article-title":"Selective low-dose spinal anesthesia for transrectal prostate biopsy: a prospective and randomized study","volume":"29","author":"Kucur","year":"2015","journal-title":"J Endourol"},{"key":"key2024100516033300_ref31-bib31","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2018.11.040","article-title":"The FUTURE trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies","volume":"75","author":"Wegelin","year":"2019","journal-title":"Eur Urol"},{"key":"key2024100516033300_ref32-bib32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MOU.0000000000000031","article-title":"Standards for prostate biopsy","volume":"24","author":"Bjurlin","year":"2014","journal-title":"Curr Opin Urol"},{"key":"key2024100516033300_ref33-bib33","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.crad.2019.03.016","article-title":"Prostate biopsy: when and how to perform","volume":"74","author":"Das","year":"2019","journal-title":"Clin Radiol"},{"key":"key2024100516033300_ref35-bib35","volume-title":"Standard Operating Procedure for Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer","author":"Fulgham","year":"2019"},{"key":"key2024100516033300_ref36-bib36","volume-title":"About Prostate Cancer","author":"Prostate Cancer Foundation","year":"2022"},{"key":"key2024100516033300_ref37-bib37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","article-title":"Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-na\u00efve patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study","volume":"20","author":"Rouviere","year":"2019","journal-title":"Lancet Oncol"},{"key":"key2024100516033300_ref38-bib38","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","article-title":"Head-to-head comparison of transrectal ultrasound-guided prostate biopsy vs. multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-na\u00efve men with elevated prostate-specific antigen: a large prospective multicenter clinical study","volume":"75","author":"van der Leest","year":"2019","journal-title":"Eur Urol"},{"key":"key2024100516033300_ref39-bib39","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"key2024100516033300_ref40-bib40","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"key2024100516033300_ref41-bib41","first-page":"S26","article-title":"Magnetic resonance imaging detects significant prostate cancer and could be used to reduce unnecessary biopsies: initial results from a prospective trial of MRI in men planned for diagnostic biopsy","volume":"82","author":"Thompson","year":"2013","journal-title":"Urology"},{"key":"key2024100516033300_ref42-bib42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41391-021-00439-9","article-title":"Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England [Published online ahead of print September 7 2021]","volume":"26","author":"Parry","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"key2024100516033300_ref43-bib43","volume-title":"Exploring the Use of a New Risk Grouping to Assess \u2018Over-Treatment\u2019 for the National Prostate Cancer Audit","author":"Morris","year":"2022"},{"key":"key2024100516033300_ref44-bib44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.21037\/tau.2017.04.30","article-title":"MRI-fusion biopsy: the contemporary experience","volume":"6","author":"Bjurlin","year":"2017","journal-title":"Transl Androl Uro"},{"key":"key2024100516033300_ref45-bib45","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2147\/JPR.S117451","article-title":"Local anesthesia for pain control during transrectal ultrasound-guided prostate biopsy: a systematic review and meta-analysis","volume":"9","author":"Yan","year":"2016","journal-title":"J Pain Res"},{"key":"key2024100516033300_ref46-bib46","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4111\/icu.20210060","article-title":"Effect of training and individual operator\u2019s expertise on prostate cancer detection through prostate biopsy: implications for the current quantitative training evaluation system","volume":"62","author":"Lee","year":"2021","journal-title":"Investig Clin Urol"},{"key":"key2024100516033300_ref47-bib47","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1148\/rg.2015140058","article-title":"MR imaging-transrectal US fusion for targeted prostate biopsies: implications for diagnosis and clinical management","volume":"35","author":"Costa","year":"2015","journal-title":"Radiographics"},{"key":"key2024100516033300_ref48-bib48","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/bju.13327","article-title":"Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging\/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure","volume":"118","author":"Cash","year":"2016","journal-title":"BJU Int"},{"key":"key2024100516033300_ref49-bib49","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/PAS.0b013e31812f7b27","article-title":"Anterior-predominant prostatic tumors: zone of origin and pathologic outcomes at radical prostatectomy","volume":"32","author":"Al-Ahmadie","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"key2024100516033300_ref50-bib50","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1046\/j.1464-410X.2002.02796.x","article-title":"Anterior prostate cancer: is it more difficult to diagnose?","volume":"89","author":"Bott","year":"2002","journal-title":"BJU Int"},{"key":"key2024100516033300_ref51-bib51","doi-asserted-by":"crossref","first-page":"734.e19","DOI":"10.1016\/j.urolonc.2020.03.020","article-title":"Systematic review and meta-analysis comparing cognitive vs. image-guided fusion prostate biopsy for the detection of prostate cancer","volume":"38","author":"Watts","year":"2020","journal-title":"Urol Oncol"},{"key":"key2024100516033300_ref52-bib52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41391-018-0075-4","article-title":"Accuracy of the magnetic resonance imaging pathway in the detection of prostate cancer: a systematic review and meta-analysis","volume":"22","author":"Sathianathen","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"key2024100516033300_ref53-bib53","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41391-021-00449-7","article-title":"Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis","volume":"25","author":"Bass","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"key2024100516033300_ref54-bib54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eururo.2014.10.026","article-title":"Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review","volume":"68","author":"Valerio","year":"2015","journal-title":"Eur Urol"},{"key":"key2024100516033300_ref55-bib55","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"key2024100516033300_ref56-bib56","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"key":"key2024100516033300_ref58-bib58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","article-title":"Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key2024100516033300_ref59-bib59","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"key2024100516033300_ref60-bib60","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine vs. androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"key":"key2024100516033300_ref61-bib61","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1002\/cncr.28270","article-title":"Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials","volume":"119","author":"Schweizer","year":"2013","journal-title":"Cancer"},{"key":"key2024100516033300_ref62-bib62","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eururo.2016.07.041","article-title":"Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore vs. magnetic resonance imaging-transrectal ultrasound fusion vs. cognitive registration. Is there a preferred technique?","volume":"71","author":"Wegelin","year":"2017","journal-title":"Eur Urol"},{"key":"key2024100516033300_ref63-bib63","article-title":"Prostate MRI, with or without MRI\u2010targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"4","author":"Drost","year":"2019","journal-title":"Cochr Datab Syst Rev"},{"key":"key2024100516033300_ref64-bib64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"key2024100516033300_ref65-bib65","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/PAS.0000000000001202","article-title":"Histopathologic false-positive diagnoses of prostate cancer in the age of immunohistochemistry","volume":"43","author":"Beltran","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"key2024100516033300_ref66-bib66","first-page":"e728","article-title":"Prostate MRI, with or without targeted biopsy, and standard biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis","volume":"18","author":"Drost","year":"2019","journal-title":"J Urol"},{"key":"key2024100516033300_ref67-bib67","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"key2024100516033300_ref68-bib68","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.7326\/M21-2234","article-title":"QUADAS-C: a tool for assessing risk of bias in comparative diagnostic accuracy studies","volume":"174","author":"Yang","year":"2021","journal-title":"Ann Intern Med"},{"key":"key2024100516033300_ref69-bib69","volume-title":"NICE DSU Technical Support Document 1: Introduction to Evidence Synthesis for Decision Making","author":"Dias","year":"2011"},{"key":"key2024100516033300_ref70-bib70","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1136\/archdischild-2018-315224","article-title":"Network meta-analysis explained","volume":"104","author":"Dias","year":"2019","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"key2024100516033300_ref71-bib71","volume-title":"NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials","author":"Dias","year":"2011"},{"key":"key2024100516033300_ref72-bib72","volume-title":"R: A Language and Environment for Statistical Computing [Software].","author":"R Core Team","year":"2022"},{"key":"key2024100516033300_ref73-bib73","volume-title":"netmeta: Network Meta-analysis Using Frequentist Methods. Version 2.5-0 ed. [Software]","author":"R\u00fccker","year":"2022"},{"key":"key2024100516033300_ref74-bib74","doi-asserted-by":"crossref","DOI":"10.1201\/b16018","volume-title":"Bayesian Data Analysis","author":"Gelman","year":"2013"},{"key":"key2024100516033300_ref75-bib75","volume-title":"The BUGS Book","author":"Lunn","year":"2013"},{"key":"key2024100516033300_ref76-bib76","volume-title":"gemtc: Network Meta-analysis Using Bayesian Methods. R Package. 1.0-1 ed. [Software]","author":"van Valkenhoef","year":"2021"},{"key":"key2024100516033300_ref77-bib77","volume-title":"NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials","author":"Dias","year":"2011"},{"key":"key2024100516033300_ref78-bib78","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"key2024100516033300_ref79-bib79","first-page":"207","article-title":"A prospective study on the efficacy of cognitive targeted transrectal ultrasound prostate biopsy in diagnosing clinically significant prostate cancer","volume":"13","author":"Thangarasu","year":"2021","journal-title":"Res Rep Urol"},{"key":"key2024100516033300_ref80-bib80","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2017.06.019","article-title":"Characteristics of prostate cancer found at fifth screening in the European randomized study of screening for prostate cancer Rotterdam: can we selectively detect high-grade prostate cancer with upfront multivariable risk stratification and magnetic resonance imaging?","volume":"73","author":"Alberts","year":"2018","journal-title":"Eur Urol"},{"key":"key2024100516033300_ref81-bib81","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00345-021-03921-0","article-title":"Diagnostic performance of fusion (US\/MRI guided) prostate biopsy: propensity score matched comparison of elastic vs. rigid fusion system","volume":"40","author":"Ferriero","year":"2022","journal-title":"World J Urol"},{"key":"key2024100516033300_ref82-bib82","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41391-021-00366-9","article-title":"Diagnostic yield of fusion magnetic resonance-guided prostate biopsy vs. cognitive-guided biopsy in biopsy-na\u00efve patients: a head-to-head randomized controlled trial","volume":"24","author":"Izadpanahi","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"key2024100516033300_ref83-bib83","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1007\/s00345-021-03761-y","article-title":"Usability and diagnostic accuracy of different MRI\/ultrasound-guided fusion biopsy systems for the detection of clinically significant and insignificant prostate cancer: a prospective cohort study","volume":"39","author":"Sokolakis","year":"2021","journal-title":"World J Urol"},{"key":"key2024100516033300_ref84-bib84","doi-asserted-by":"crossref","first-page":"649","DOI":"10.15537\/smj.2021.42.6.20200771","article-title":"Transperineal vs. transrectal multi-parametric magnetic resonance imaging fusion targeted prostate biopsy","volume":"42","author":"Rabah","year":"2021","journal-title":"Saudi Med J"},{"key":"key2024100516033300_ref85-bib85","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1089\/end.2020.0276","article-title":"A comparative study of prostate cancer detection rate between transperineal COG-TB and transperineal FUS-TB in patients with PSA <=20\u2009ng\/mL","volume":"34","author":"Liang","year":"2020","journal-title":"J Endourol"},{"key":"key2024100516033300_ref86-bib86","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3325\/cmj.2020.61.49","article-title":"Targeted prostate biopsy using a cognitive fusion of multiparametric magnetic resonance imaging and transrectal ultrasound in patients with previously negative systematic biopsies and non-suspicious digital rectal exam","volume":"61","author":"Kulis","year":"2020","journal-title":"Croat Med J"},{"key":"key2024100516033300_ref87-bib87","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/bju.14957","article-title":"A cohort of transperineal electromagnetically tracked magnetic resonance imaging\/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection","volume":"125","author":"Wajswol","year":"2020","journal-title":"BJU Int"},{"key":"key2024100516033300_ref88-bib88","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamasurg.2019.1734","article-title":"Comparison of targeted vs systematic prostate biopsy in men who are biopsy na\u00efve: the prospective assessment of image registration in the diagnosis of prostate cancer (PAIREDCAP) study","volume":"154","author":"Elkhoury","year":"2019","journal-title":"JAMA Surg"},{"key":"key2024100516033300_ref89-bib89","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.euo.2018.02.002","article-title":"Not all multiparametric magnetic resonance imaging-targeted biopsies are equal: the impact of the type of approach and operator expertise on the detection of clinically significant prostate cancer","volume":"1","author":"Stabile","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"key2024100516033300_ref90-bib90","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.urology.2018.06.011","article-title":"Cognitive vs. software fusion for MRI-targeted biopsy: experience before and after implementation of fusion","volume":"119","author":"Monda","year":"2018","journal-title":"Urology"},{"key":"key2024100516033300_ref91-bib91","doi-asserted-by":"crossref","first-page":"e953","DOI":"10.1016\/j.clgc.2018.03.013","article-title":"Cognitive vs. software-assisted registration: development of a new nomogram predicting prostate cancer at MRI-targeted biopsies","volume":"16","author":"Kaufmann","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"key2024100516033300_ref92-bib92","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/21681805.2018.1438509","article-title":"The combination of targeted and systematic prostate biopsies is the best protocol for the detection of clinically significant prostate cancer","volume":"52","author":"Fourcade","year":"2018","journal-title":"Scand J Urol"},{"key":"key2024100516033300_ref93-bib93","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1148\/radiol.2017162916","article-title":"Precision matters in MR imaging-targeted prostate biopsies: evidence from a prospective study of cognitive and elastic fusion registration transrectal biopsies","volume":"287","author":"Cornud","year":"2018","journal-title":"Radiology"},{"key":"key2024100516033300_ref94-bib94","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.purol.2017.10.001","article-title":"Are concurrent systematic cores needed at the time of targeted biopsy in patients with prior negative prostate biopsies?","volume":"28","author":"Albisinni","year":"2018","journal-title":"Prog Urol"},{"key":"key2024100516033300_ref95-bib95","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bju.14049","article-title":"Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-na\u00efve men with suspicion of prostate cancer","volume":"122","author":"Hansen","year":"2018","journal-title":"BJU Int"},{"key":"key2024100516033300_ref96-bib96","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.29874","article-title":"Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies","volume":"122","author":"Filson","year":"2016","journal-title":"Cancer"},{"key":"key2024100516033300_ref97-bib97","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2013.10.048","article-title":"A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial","volume":"66","author":"Wysock","year":"2014","journal-title":"Eur Urol"},{"key":"key2024100516033300_ref98-bib98","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.juro.2012.08.195","article-title":"Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies","volume":"189","author":"Delongchamps","year":"2013","journal-title":"J Urol"},{"key":"key2024100516033300_ref99-bib99","first-page":"212","article-title":"Routine systematic prostate biopsies not replaced by magnetic resonance imaging-targeted biopsy [published online ahead of print June 7 2022]","volume":"74","author":"Gomez-Ortiz","year":"2022","journal-title":"Rev Invest Clin"},{"key":"key2024100516033300_ref100-bib100","volume-title":"J Clin Urol","author":"Lockhart"},{"key":"key2024100516033300_ref101-bib101","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00345-018-2189-7","article-title":"Prostate cancer detection in patients with prior negative biopsy undergoing cognitive-, robotic- or in-bore MRI target biopsy","volume":"36","author":"Kaufmann","year":"2018","journal-title":"World J Urol"},{"key":"key2024100516033300_ref102-bib102","doi-asserted-by":"crossref","DOI":"10.1201\/9781498710411","volume-title":"Usability Evaluation in Industry","author":"Jordan","year":"1996"},{"key":"key2024100516033300_ref103-bib103","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key2024100516033300_ref104-bib104","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated vs. conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"key2024100516033300_ref105-bib105","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"key2024100516033300_ref106-bib106","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional vs. hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"key2024100516033300_ref107-bib107","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated vs. conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"key2024100516033300_ref108-bib108","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1756-9966-28-117","article-title":"Modeling of alpha\/beta for late rectal toxicity from a randomized phase II study: conventional vs. hypofractionated scheme for localized prostate cancer","volume":"28","author":"Marzi","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"key2024100516033300_ref109-bib109","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1113162","article-title":"Radical prostatectomy vs. observation for localized prostate cancer","volume":"367","author":"Wilt","year":"2012","journal-title":"N Engl J Med"},{"key":"key2024100516033300_ref110-bib110","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa1011967","article-title":"Radical prostatectomy vs. watchful waiting in early prostate cancer","volume":"364","author":"Bill-Axelson","year":"2011","journal-title":"N Engl J Med"},{"key":"key2024100516033300_ref111-bib111","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.brachy.2017.07.008","article-title":"Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy","volume":"16","author":"Hegde","year":"2017","journal-title":"Brachytherapy"},{"key":"key2024100516033300_ref112-bib112","doi-asserted-by":"crossref","first-page":"e1002063","DOI":"10.1371\/journal.pmed.1002063","article-title":"Improving clinical risk stratification at diagnosis in primary prostate cancer: a prognostic modelling study","volume":"13","author":"Gnanapragasam","year":"2016","journal-title":"PLOS Med"},{"key":"key2024100516033300_ref113-bib113","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \u2018docetaxel era\u2019: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur Urol"},{"key":"key2024100516033300_ref114-bib114","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/bju.14987","article-title":"The PROTecT trial: analysis of the patient cohort, baseline risk stratification and disease progression","volume":"125","author":"Bryant","year":"2020","journal-title":"BJU Int"},{"key":"key2024100516033300_ref115-bib115","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s41669-018-0109-9","article-title":"Use of decision modelling in economic evaluations of diagnostic tests: an appraisal and review of Health Technology Assessments in the UK","volume":"3","author":"Yang","year":"2019","journal-title":"PharmacoEcon Open"},{"key":"key2024100516033300_ref116-bib116","volume-title":"Transperineal Biopsy in People with Suspected Prostate Cancer: A Systematic Review and Economic Evaluation","author":"Souto-Ribeiro","year":"2022"},{"key":"key2024100516033300_ref117-bib117","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1148\/radiol.2017162181","article-title":"Cost-effectiveness of MR imaging-guided strategies for detection of prostate cancer in biopsy-na\u00efve men","volume":"285","author":"Pahwa","year":"2017","journal-title":"Radiology"},{"key":"key2024100516033300_ref118-bib118","doi-asserted-by":"crossref","first-page":"853","DOI":"10.7326\/0003-4819-158-12-201306180-00002","article-title":"Observation vs. initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis","volume":"158","author":"Hayes","year":"2013","journal-title":"Ann Intern Med"},{"key":"key2024100516033300_ref119-bib119","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1186\/s12913-021-06916-0","article-title":"Cost-effectiveness of MRI targeted biopsy strategies for diagnosing prostate cancer in Singapore","volume":"21","author":"Cheng","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"key2024100516033300_ref120-bib120","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jval.2021.06.001","article-title":"Cost-effectiveness of magnetic resonance imaging in prostate cancer screening: a microsimulation study","volume":"24","author":"Hao","year":"2021","journal-title":"Value Health"},{"key":"key2024100516033300_ref121-bib121","first-page":"737","article-title":"Economic evaluation of transperineal vs. transrectal devices for local anaesthetic prostate biopsies","volume":"5","author":"Wilson","year":"2021","journal-title":"PharmacoEcon"},{"key":"key2024100516033300_ref122-bib122","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1002\/cam4.3932","article-title":"Cost-effectiveness of multiparametric magnetic resonance imaging and MRI-guided biopsy in a population-based prostate cancer screening setting using a micro-simulation model","volume":"10","author":"Getaneh","year":"2021","journal-title":"Cancer Medicine"},{"key":"key2024100516033300_ref124-bib124","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bju.14151","article-title":"Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer","volume":"122","author":"Barnett","year":"2018","journal-title":"BJU Int"},{"key":"key2024100516033300_ref125-bib125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2017.08.018","article-title":"Optimising the diagnosis of prostate cancer in the era of multiparametric magnetic resonance imaging: a cost-effectiveness analysis based on the prostate MR imaging study (PROMIS)","volume":"73","author":"Faria","year":"2018","journal-title":"Eur Urol"},{"key":"key2024100516033300_ref126-bib126","first-page":"1","article-title":"Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study","volume":"22","author":"Brown","year":"2018","journal-title":"Health Technol Assess"},{"key":"key2024100516033300_ref127-bib127","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.euo.2018.05.007","article-title":"The role of multiparametric magnetic resonance imaging in active surveillance for men with low-risk prostate cancer: a cost-effectiveness modeling study","volume":"1","author":"Patel","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"key2024100516033300_ref128-bib128","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.juro.2018.06.016","article-title":"Incorporating biomarkers into the primary prostate biopsy setting: a cost-effectiveness analysis","volume":"200","author":"Sathianathen","year":"2018","journal-title":"J Urol"},{"key":"key2024100516033300_ref129-bib129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1148\/radiol.2017162181","article-title":"MR imaging-guided strategies for detection of prostate cancer in biopsy-na\u00efve men: response","volume":"285","author":"Pahwa","year":"2017","journal-title":"Radiology"},{"key":"key2024100516033300_ref130-bib130","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2214\/AJR.16.17322","article-title":"Cost-effectiveness comparison of imaging-guided prostate biopsy techniques: systematic transrectal ultrasound, direct in-bore MRI, and image fusion","volume":"208","author":"Venderink","year":"2017","journal-title":"AJR: Am J Roentgenol"},{"key":"key2024100516033300_ref131-bib131","doi-asserted-by":"crossref","first-page":"119.e1","DOI":"10.1016\/j.urolonc.2015.09.010","article-title":"Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer","volume":"34","author":"Cerantola","year":"2016","journal-title":"Urol Oncol"},{"key":"key2024100516033300_ref132-bib132","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2013.12.012","article-title":"Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy vs. systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective","volume":"66","author":"de Rooij","year":"2014","journal-title":"Eur Urol"},{"key":"key2024100516033300_ref133-bib133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17200","article-title":"The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation","volume":"17","author":"Mowatt","year":"2013","journal-title":"Health Technol Assess"},{"key":"key2024100516033300_ref135-bib135","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1311593","article-title":"Radical prostatectomy or watchful waiting in early prostate cancer","volume":"370","author":"Bill-Axelson","year":"2014","journal-title":"N Engl J Med"},{"key":"key2024100516033300_ref136-bib136","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3109\/0284186X.2012.760848","article-title":"Health-related quality of life in prostate cancer","volume":"52","author":"Torvinen","year":"2013","journal-title":"Acta Oncol"},{"key":"key2024100516033300_ref137-bib137","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"key":"key2024100516033300_ref138-bib138","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N Engl J Med"},{"key":"key2024100516033300_ref139-bib139","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0269216315595203","article-title":"Estimating the cost of caring for people with cancer at the end of life: a modelling study","volume":"29","author":"Round","year":"2015","journal-title":"Palliat Med"},{"key":"key2024100516033300_ref140-bib140","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS: a Bayesian modelling framework: concepts, structure, and extensibility","volume":"10","author":"Lunn","year":"2000","journal-title":"Stat Comput"},{"key":"key2024100516033300_ref141-bib141","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.juro.2018.02.067","article-title":"Diagnostic accuracy of multiparametric magnetic resonance imaging and fusion guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer","volume":"200","author":"Mortezavi","year":"2018","journal-title":"J Urol"},{"key":"key2024100516033300_ref142-bib142","doi-asserted-by":"crossref","first-page":"e12495","DOI":"10.1097\/MD.0000000000012495","article-title":"Diagnostic accuracy of magnetic resonance-guided prostate biopsy and template-guided transperineal saturation biopsy","volume":"97","author":"Zhou","year":"2018","journal-title":"Medicine"},{"key":"key2024100516033300_ref143-bib143","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"key":"key2024100516033300_ref144-bib144","volume-title":"National Life Tables: UK","author":"Office for National Statistics","year":"2021"},{"key":"key2024100516033300_ref145-bib145","volume-title":"WebPlotDigitizer","author":"Ankit Rohatgi","year":"2022"},{"key":"key2024100516033300_ref146-bib146","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"key2024100516033300_ref147-bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v070.i08","article-title":"flexsurv: a platform for parametric survival modeling in R","volume":"70","author":"Jackson","year":"2016","journal-title":"J Stat Softw"},{"key":"key2024100516033300_ref149-bib149","volume-title":"ESMO 2021: Final Overall Survival Analysis from ARCHES: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Enzalutamide + ADT in Men with mHSPC","author":"Wallis","year":"2021"},{"key":"key2024100516033300_ref150-bib150","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"key2024100516033300_ref151-bib151","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12916-020-01588-9","article-title":"Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation","volume":"18","author":"Parry","year":"2020","journal-title":"BMC Med"},{"key":"key2024100516033300_ref152-bib152","volume-title":"Transperineal Biopsy in People with Suspected Prostate Cancer: A Systematic Review and Economic Evaluation. Addendum 1","author":"Souto-Ribeiro","year":"2022"},{"key":"key2024100516033300_ref153-bib153","doi-asserted-by":"crossref","first-page":"S1300","DOI":"10.1016\/j.annonc.2021.08.2101","article-title":"LBA25 final overall survival (OS) analysis from ARCHES: a phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"32","author":"Armstrong","year":"2021","journal-title":"Ann Oncol"},{"key":"key2024100516033300_ref154-bib154","volume-title":"Unit Costs of Health and Social Care 2021","author":"Jones","year":"2021"},{"key":"key2024100516033300_ref155-bib155","volume-title":"Imperial Prostate 7: Prostate Assessment Using Comparative Interventions \u2013 Fast MRI and Image-Fusion for Cancer (IP7-PACIFIC). ClinicalTrials.gov","author":"Imperial College London","year":"2022"},{"key":"key2024100516033300_ref156-bib156","volume-title":"Doing Bayesian Data Analysis: A Tutorial with R and BUGS","author":"Kruschke","year":"2010"},{"key":"key2024100516033300_ref157-bib157","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0272989X03255922","article-title":"Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework","volume":"23","author":"Briggs","year":"2003","journal-title":"Med Decis Making"},{"key":"key2024100516033300_ref158-bib158","doi-asserted-by":"crossref","first-page":"62","DOI":"10.48083\/KKVJ7280","article-title":"E Prostate cancer detection by novice micro-ultrasound users enrolled in a training program","volume":"3","author":"Cash","year":"2022","journal-title":"Soc Int Urol J"},{"key":"key2024100516033300_ref159-bib159","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2019.06.005","article-title":"Is there still a need for repeated systematic biopsies in patients with previous negative biopsies in the era of magnetic resonance imaging-targeted biopsies of the prostate?","volume":"3","author":"Exterkate","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"key2024100516033300_ref160-bib160","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/jmri.24629","article-title":"Registration of in vivo prostate MRI and pseudo-whole mount histology using Local Affine Transformations guided by Internal Structures (LATIS)","volume":"41","author":"Kalavagunta","year":"2015","journal-title":"J Magn Reson Imaging"},{"key":"key2024100516033300_ref161-bib161","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.euo.2019.08.007","article-title":"Complications and adverse events of three magnetic resonance imaging-based target biopsy techniques in the diagnosis of prostate cancer among men with prior negative biopsies: results from the FUTURE trial, a multicentre randomised controlled trial","volume":"2","author":"Wegelin","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"key2024100516033300_ref162-bib162","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bju.15093","article-title":"Detection of clinically significant prostate cancer in biopsy-na\u00efve men: direct comparison of systematic biopsy, multiparametric MRI- and contrast-ultrasound-dispersion imaging-targeted biopsy","volume":"126","author":"Mannaerts","year":"2020","journal-title":"BJU Int"},{"key":"key2024100516033300_ref163-bib163","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.juro.2018.07.001","article-title":"Accuracy of transperineal targeted prostate biopsies, visual estimation and image fusion in men needing repeat biopsy in the PICTURE trial","volume":"200","author":"Simmons","year":"2018","journal-title":"J Urol"},{"key":"key2024100516033300_ref164-bib164","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.eururo.2016.02.064","article-title":"Magnetic resonance and ultrasound image fusion supported transperineal prostate biopsy using the Ginsburg protocol: technique, learning points, and biopsy results","volume":"70","author":"Hansen","year":"2016","journal-title":"Eur Urol"},{"key":"key2024100516033300_ref165-bib165","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000458764","article-title":"TOP: Prospective evaluation of a volume based, computer assisted method for transperineal optimized prostate biopsy","volume":"99","author":"Kesch","year":"2017","journal-title":"Urol Int"},{"key":"key2024100516033300_ref166-bib166","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.urology.2016.04.037","article-title":"Multiparametric prostate magnetic resonance imaging and cognitively targeted transperineal biopsy in patients with previous abdominoperineal resection and suspicion of prostate cancer","volume":"96","author":"Hansen","year":"2016","journal-title":"Urology"},{"key":"key2024100516033300_ref167-bib167","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.ijrobp.2020.07.2194","article-title":"An updated analysis of survival endpoints for ASCENDE-RT, a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"108","author":"Oh","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key2024100516033300_ref168-bib168","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7748\/cnp.2017.e1417","article-title":"Multi-parametric magnetic resonance imaging before prostate biopsy","volume":"16","author":"Hedley","year":"2017","journal-title":"Cancer Nurs Pract"},{"key":"key2024100516033300_ref169-bib169","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijrobp.2019.09.007","article-title":"Hyprofractionated vs. conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial","volume":"106","author":"de Vries","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key2024100516033300_ref170-bib170","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/JCO.2020.38.6_suppl.325","article-title":"Eight-year outcomes of a phase III randomized trial of conventional vs. hypofractionated high-dose intensity modulated radiotherapy for prostate cancer (CRUK\/06\/016): update from the CHHiP Trial","volume":"38","author":"David","year":"2020","journal-title":"J Clin Oncol"},{"key":"key2024100516033300_ref171-bib171","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","article-title":"Ultra-hypofractionated vs. conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial","volume":"22","author":"Fransson","year":"2021","journal-title":"Lancet Oncol"},{"key":"key2024100516033300_ref172-bib172","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.eururo.2020.02.009","article-title":"Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the prostate cancer intervention vs. observation trial (PIVOT)","volume":"77","author":"Wilt","year":"2020","journal-title":"Eur Urol"},{"key":"key2024100516033300_ref173-bib173","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa1807801","article-title":"Radical prostatectomy or watchful waiting in prostate cancer: 29-year follow-up","volume":"379","author":"Bill-Axelson","year":"2018","journal-title":"N Engl J Med"},{"key":"key2024100516033300_ref174-bib174","doi-asserted-by":"crossref","first-page":"viii271","DOI":"10.1093\/annonc\/mdy284","article-title":"Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up","volume":"29","author":"Fizazi","year":"2018","journal-title":"Ann Oncol"},{"key":"key2024100516033300_ref175-bib175","doi-asserted-by":"crossref","first-page":"d7894","DOI":"10.1136\/bmj.d7894","article-title":"Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within Protect study","volume":"344","author":"Rosario","year":"2012","journal-title":"BMJ"},{"key":"key2024100516033300_ref176-bib176","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.urology.2013.02.019","article-title":"Morbidity after transperineal prostate biopsy in 3000 patients undergoing 12 vs 18 vs more than 24 needle cores","volume":"81","author":"Pepe","year":"2013","journal-title":"Urology"},{"key":"key2024100516033300_ref177-bib177","first-page":"62","article-title":"P9-7 The clinical and financial implications of a decade of prostate biopsies in the NHS: interrogation of the Hospital Episode Statistics (HES) Data 2008-2019 [BAUS abstracts]","volume":"13","author":"Tamhankar","year":"2020","journal-title":"J Clin Urol"},{"key":"key2024100516033300_ref178-bib178","volume-title":"2018\/19 National Cost Collection Data Publication","author":"NHS England","year":"2021"},{"key":"key2024100516033300_ref179-bib179","volume-title":"2019\/20 National Cost Collection Data Publication","author":"NHS England","year":"2021"},{"key":"key2024100516033300_ref180-bib180","volume-title":"2020\/2021 National Cost Collection Data","author":"NHS England","year":"2022"},{"key":"key2024100516033300_ref181-bib181","volume-title":"Table of NHS Provider-Level Results: National Prostate Cancer Audit","author":"NPCA Organisational Audit 2021","year":"2022"},{"key":"key2024100516033300_ref183-bib183","volume-title":"US Dollar (USD) to British Pound (GBP) Exchange Rate History: Wednesday 9\/03\/2022 to Saturday 3\/09\/2022","author":"Exchange Rates UK","year":"2022"},{"key":"key2024100516033300_ref184-bib184","volume-title":"Drugs and Pharmaceutical Electronic Market Information Tool (eMIT)","year":"2021"},{"key":"key2024100516033300_ref185-bib185","volume-title":"BMJ Group and the Royal Pharmaceutical Society of Great Britain","author":"British National Formulary (BNF)","year":"2022"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2046266","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/PLFG4210\/PLFG4210.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2046266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T10:40:20Z","timestamp":1728124820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/PLFG4210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":171,"alternative-id":["10.3310\/PLFG4210"],"URL":"https:\/\/doi.org\/10.3310\/plfg4210","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"05-2022","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"12-2022","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"06-2023","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}